Rhinitis, Allergic Clinical Trial
Official title:
Assessment of the Effectiveness of Regular Use of Intranasal Steroids in Alleviating Nasal Symptoms in Allergic Rhinitis When Used Alone or in Combination With Oral Antihistamine
Verified date | February 2022 |
Source | Organon and Co |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 4, non-comparative, open-label, multi-center study. It is designed to determine the effectiveness of regular intranasal steroid use in alleviating allergic rhinitis nasal symptoms, when used alone or in combination with an oral antihistamine. Subjects will receive 200 mcg (2 puffs in each nostril) of mometasone furoate once a day. An oral antihistamine at the discretion of the physician may be added at Day 28 (Visit 2), if patients fail to improve nasal symptoms.
Status | Completed |
Enrollment | 72 |
Est. completion date | April 1, 2004 |
Est. primary completion date | April 1, 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent form - Subjects must be between 18-65 years of age, of either sex and any race - Subjects must be diagnosed by the physician to have moderate to severe allergic rhinitis according to ARIA guidelines. - Subjects must be mometasone furoate naïve. Exclusion Criteria: - Significant comorbid medical condition. - Respiratory tract infection. - Any contraindications according to mometasone furoate product monograph. - Patients who have received antihistamine treatment within the last 5 days. - Patients who have received corticosteroid treatment within the last 30 days. - Patients who are likely to require the administration of systemic steroids during the course of this program. - Any condition which in the doctor's opinion could interfere with the patient completion of this program. - Pregnant or lactating patients. - Patients with local infections involving the nasal mucosa. - Patients with structural abnormalities or who have undergone nasal surgery or trauma in the past 6 months. - Patients with hypersensitivity to mometasone furoate or are allergic to corticosteroids. - Patients who are prone to nose bleeding. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Organon and Co |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the mean change in total nasal symptom score from Baseline to the Final Visit of regular intranasal steroid use (mometasone furoate) in allergic rhinitis patients when used alone or in combination with an oral antihistamine. | Day 28 and Day 56 | ||
Secondary | Patient satisfaction with intranasal steroid monotherapy. | Day 28 | ||
Secondary | Potential benefit of an oral antihistamine in combination with an intranasal steroid | Day 56 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02424539 -
A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)
|
Phase 4 | |
Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
Completed |
NCT02486159 -
The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture
|
N/A | |
Completed |
NCT00771160 -
MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Recruiting |
NCT05621356 -
Monitoring Allergen Immunotherapy in Allergic Rhinitis
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT03758456 -
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
|
Phase 1 | |
Completed |
NCT04645979 -
A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
|
||
Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
Completed |
NCT05901532 -
Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis
|
Phase 2 | |
Terminated |
NCT02722083 -
Exploratory Study for Allergy Relief Onset
|
Phase 2 | |
Recruiting |
NCT05656482 -
Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
|
||
Recruiting |
NCT04898283 -
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
|
Phase 3 | |
Recruiting |
NCT06436534 -
Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis
|
N/A | |
Recruiting |
NCT05922176 -
Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
|
||
Completed |
NCT02679105 -
Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy
|
Phase 2/Phase 3 | |
Completed |
NCT01104012 -
Validation of Proteomic Analyses for Allergic Asthma and Rhinitis
|
N/A | |
Completed |
NCT03375775 -
Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children
|
N/A |